Breaking News

AbbVie Acquires API Mfg. Site in Singapore

Expands capacity for immunology and oncology pipelines

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie has acquired a small molecule API manufacturing site in Singapore’s Tuas Biomedical Park, expanding its global operations for small molecule and biologics. AbbVie’s first manufacturing facility in Asia, the 120,000 square meter site increases capacity for compounds in its immunology and oncology pipelines. It includes a contained API facility, additional buildings, and ancillary equipment. The API facility is expected to be fully operational by 2016.   AbbVie will also constru...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters